Fresenius Medical cuts 2026 profit forecast amid declining treatments in the US

Fresenius Medical has revised its 2026 profit outlook downward due to a deepening decline in treatment volumes in the US. According to a Reuters report, the company stated that the decrease in treatment demand in the US market was behind this decision. The company's reduction of its 2026 profit forecast indicates that the decline in US treatment volumes is more pronounced than expected. This situation increases uncertainties regarding Fresenius Medical's future financial performance. The report cites the deepening decline in US treatments as one of the reasons for the lowered profit outlook. The company anticipates that this development will negatively affect its profitability in 2026. The implications for Fresenius Medical's stock and financial markets will be closely watched by investors. The company's statements clarify the impact of treatment trends in the US market on the company. Not investment advice.

📊 GOOGL — Piyasa Yorumu

■ neutral · 35%

The news headline pertains to Fresenius Medical and has no direct connection to GOOGL's fundamental dynamics; therefore, its impact on the stock will likely remain limited and indirect. The technical picture is weak: the price is below the SMA20 and SMA50, MACD is in negative territory, and RSI14 stands at 36, indicating that selling pressure persists in the short term. However, the RSI's approach to oversold territory also brings a possibility of limited rebound buying. Since the news belongs to a sector-specific healthcare company, it does not generate a clear directional signal for GOOGL. Therefore, a neutral stance appears more realistic in the short term.

RSI 14

36.1

MACD

-5.12

24h Δ

-0.71%

Canlı Grafikler